If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 7 of 7
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Objective
To compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations.
Protocol No
NRG-CC008
Categories
Psycho-Spiritual Management for Patients with Advanced Cancer and their Family Caregivers
Objective
Psycho-Spiritual Management for Patients with Advanced Cancer and Family Caregivers
Protocol No
MDACC-2023-0450
REMASTer: REcurrent Brain Metastases After SRS Trial
Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer,
Endocrine Cancers,
Uterine,
Other Urologic,
Colorectal,
Cervix,
Lung,
Brain and Spine Cancers,
Prostate,
Stomach,
Skin Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Breast Cancers,
Head and Neck Cancers,
Esophagus,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers
A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors
Objective
The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS3939-077
Categories
A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants with Advanced Solid Tumors
Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
Cancer,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Other Skin,
Other Respiratory,
Colorectal,
Pancreas/Liver,
Skin Cancers,
Other Gynecologic,
Other Gastrointestinal,
Ovary,
Prostate,
Thoracic Cancers,
Gastrointestinal Cancers,
Sarcoma,
Uterine,
Kidney,
Gynecologic Cancers,
Breast Cancers,
Eye/Orbital Cancers,
Head and Neck Cancers,
Other Urologic,
Endocrine Cancers,
Prostate and Urologic Cancers
Open-Label Phase II Trial of Enfortumab Vedotin in Recurrent or Persistent Endometrial Carcinoma
Objective
In this project we want to find out more about an investigational drug, EV, and how well it works in treating endometrial cancer. We also want to find out how safe the drug is and what side effects it may cause for the people who take it.
Protocol No
IIT-BRADLEY-ASTELLAS-EV-EC
Categories
A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy
Objective
Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative RT
Protocol No
SIO-TRIBUTE